SILO Pharma IncSILO
Price$1.50

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $72.1K0.0% YoYTTM through 31 Dec 2025
Net Income -$4.2MTTM through 31 Dec 2025
Free Cash Flow -$4.7MTTM through 31 Dec 2025

Margins

Current
Gross Margin91.9%
Operating Margin-6,526.4%
Net Margin-5,863.5%

Returns

-67.1%ROE
-55.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio11.36x
Net Debt-$7.1Mnet cash position
Cash & Equivalents$4.8M

Quality Metrics

FCF Margin-6,471.1%
Earnings-Beat Rate50.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Clinical Trials$72.1K0.0%
View details

The company continues to focus on advancing its clinical pipeline toward IND submissions and clinical trials, supported by strategic technology acquisitions and academic collaborations.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.